Maze Therapeutics said on Thursday that it raised $140 million in an initial public offering, setting the stage for a debut that will make the kidney disease drug developer the first U.S. biotech ...
A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care ...
Pimco, one of the world’s largest bond managers, owns 354 million Class A shares of Venture Global (VG), the natural-gas exporter that went ...
Shares in Venture Global are expected to make their debut on the New York Stock Exchange after the company raised $1.75 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback